• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Insmed Initiates ARIKAYCE Trial for MAC Lung Disease americanpharmaceuticalreview
    January 11, 2021
    Insmed announced the first patient was dosed in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
  • EC Grants Authorization for ARIKAYCE Liposomal Nebulizer Dispersion for NTM Lung Infections americanpharmaceuticalreview
    November 06, 2020
    Insmed Incorporated announced the European Commission (EC) has granted marketing authorization for ARIKAYCE® Liposomal 590 mg Nebulizer Dispersion for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service